DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Free Float of BRAIN share successfully increased

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Miscellaneous B.R.A.I.N. Biotechnology Research And Information Network AG: Free Float of BRAIN share successfully increased 09.02.2017 / 11:04 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Free Float of BRAIN share successfully increased Zwingenberg, February 9, 2017: Yesterday evening, B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) was informed that after the end of the one-year lock-up period, MIG Fonds, as existing shareholders of the company, sold its entire stake of 2,528,389 shares to more than 20 institutional investors. The placement took place outside the stock market as part of an accelerated book-building process. The transaction, which was oversubscribed several times, was accompanied by ODDO SEYDLER BANK AG and Baader Bank AG. The free float of BRAIN shares increased from 22% to 37%. Dr Jürgen Eck, CEO of BRAIN AG, is pleased about the strong demand from investor interest for the BRAIN share: "The MiG funds are early-stage investors, which provide venture capital for founders and young companies. They have financially supported the development of BRAIN AG for many years and have thus also contributed significantly to our success. I would therefore like to expressly thank you for the excellent and trustworthy cooperation in recent years. The high demand on the part of the investors is a further confirmation of our operating business." "As a result of the placement, the free float of BRAIN share has significantly increased, which will also improve the tradability of the share for all investors. I am satisfied that based on the high demand from investors, a successful transaction for the MiG funds could be carried out as Joint Global Coordinator by the accompanying banks ODDO SEYDLER BANK AG together with BAADER BANK AG as joint bookrunners", says Frank Goebel, Member of the Management Board of BRAIN AG. About BRAIN BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars - "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive - collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain- biotech.de/en Contact: B.R.A.I.N Biotechnology Research And Information Network AG Dr. Martin Langer Executive Vice President Corporate Development Darmstädter Str. 34-36 64673 Zwingenberg, Germany Tel.: +49-6251-9331-16 Fax: +49-6251-9331-11 E-Mail: ir@brain-biotech.de www.brain-biotech.de Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward- looking statements. --------------------------------------------------------------------------- 09.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: ir@brain-biotech.de Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 543277 09.02.2017

Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 8,76 10,37 21,13 22,79 24,11 27,05 38,56 43,00
EBITDA1,2 -3,72 -3,81 -3,10 -12,36 -7,70 -6,55 -2,47 -0,50
EBITDA-Marge3 -42,47 -36,74 -14,67 -54,23 -31,94 -24,21 -6,41 -1,16
EBIT1,4 -4,39 -4,82 -4,57 -13,81 -9,37 -9,57 -7,17 -3,70
EBIT-Marge5 -50,11 -46,48 -21,63 -60,60 -38,86 -35,38 -18,59 -8,60
Jahresüberschuss1 0,00 -4,52 -5,47 -14,43 -9,40 -8,37 -10,49 -4,90
Netto-Marge6 0,00 -43,59 -25,89 -63,32 -38,99 -30,94 -27,20 -11,40
Cashflow1,7 -4,85 -3,90 -4,11 -8,68 -5,80 -5,42 -3,38 -1,10
Ergebnis je Aktie8 -0,28 -0,33 -0.36 -0,97 -0,58 -0,45 -0,58 -0,27
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

BRAIN Biotechology
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 8,620 155,64
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 17,17 0,000 -18,07
12,72 - 4,04 -70,125
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 05.03.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2020 29.05.2020 31.08.2020 14.01.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
10,22% -8,57% -20,19% -15,49%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei DGAP abrufen

Biotechnologie , 520394 , BNN , XETR:BNN